Mesothelin/GPC3/GUCY2C-CAR-T Cells Against Cancers
About the study
Who can take part
INCLUSION CRITERIA
Inclusion Criteria:
1. Patients with advanced cancer that expresses Mesothelin protein; 2. Life expectancy >12 weeks; 3. Adequate heart, lung, liver, kidney, and blood function; 4. Available autologous transduced T cells with greater than or equal to 20% expression of Mesothelin-CAR determined by flow-cytometry and killing of Mesothelin-positive targets greater than or equal to 20% in cytotoxicity assay; 5. Informed consent explained to, understood by and signed by patient/guardian. Patient/guardian given copy of informed consent.
-
EXCLUSION CRITERIA
Exclusion Criteria:
- Had accepted gene therapy before;
- Severe virus infection such as HBV, HCV, HIV, et al;
- Known HIV positivity;
- Active infectious disease related to bacteria, virus,fungi,et al;
- Other severe diseases that the investigators consider not appropriate;
- Pregnant or lactating women;
- Systemic steroid treatment (greater than or equal to 0.5 mg prednisone equivalent/kg/day);
- Other conditions that the investigators consider not appropriate. -
Study Locations
Enter your ZIP code/Postal code/PIN code to locate study sites near you:
How to Apply
Study Details
Contition
Pancreas Cancer,CAR-T Cell Therapy,Mesothelin,Solid Tumor, Adult
Age
18 - 75
Phase
PHASE1
Participants Needed
30
Est. Completion Date
Mar 10, 2036
Treatment Type
INTERVENTIONAL
Sponsor
Second Affiliated Hospital of Guangzhou Medical University
ClinicalTrials.gov NCT Identifier
NCT05779917
Study Number
FC-004
Understanding Clinical Trials
Get answers to your questions about clinical trials.What is clinical research?What does taking part in clinical trials involve?What should I ask the trial doctor?